-
Trametinib, sold
under the
brand name
Mekinist among others, is an
anticancer medication used for the
treatment of
melanoma and glioma. It is a MEK inhibitor...
- rash,
joint pain,
fever and tiredness. When
taken in
combination with
trametinib, the most
common side
effects include fever, tiredness, nausea, chills...
- BRAF inhibitors, such as
vemurafenib and
dabrafenib and a MEK
inhibitor trametinib are the most effective,
approved treatments for BRAF
positive melanoma...
- Fecher,
Leslie A.; et al. (2012). "Activity of the oral MEK
inhibitor trametinib in
patients with
advanced melanoma: a
phase 1 dose-escalation trial"....
-
evaluated as a
combination treatment against solid tumors together with
trametinib in a
clinical trial sponsored by the
National Cancer Institute. In this...
- of NSCLC) can be
treated by
dabrafenib combined with the MEK
inhibitor trametinib;
those with
activated ROS1 (around 1% of NSCLC) can be
inhibited by crizotinib...
- BRAF inhibitors, such as
vemurafenib and dabrafenib; and a MEK
inhibitor trametinib.
Important prognosis factors for
nodular melanoma include:
Thickness Ulceration...
-
metastatic melanoma that
harbors BRAF V600E
mutation MEK
inhibitors (
trametinib, MEK162) are used in experiments,
often in
combination with BRAF inhibitors...
-
Rosuvastatin Crestor 1.37 in
hemodialysis patients Lisinopril Prinivil and
others 1.38
Ivacaftor Kalydeco 2.2–2.9
Trametinib Mekinist 6.0 at 2 mg once daily...
-
thyroid cancer harboring such mutations. The
combination of
dabrafenib and
trametinib has
shown significant increases in
overall survival and has been approved...
